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Does absolute excess of alpha chains 
compromise the benefit of splenectomy in patients
with thalassemia intermedia?
b thalassemia intermedia (TI) is a clinical definition refer-
ring to a heterogeneous group of hereditary anemias
resulting from defective b chain production, an α/b globin
chain imbalance, and anemia that lie in severity between
that of thalassemia minor and the transfusion-dependent
thalassemia major (TM).1 The phenotype of TI may also
result from the increased production of α globin chains by
a triplicated or quadruplicated α genotype associated with
b heterozygosity, also leading to α/b globin chain imbal-
ance, and a presumably mild clinical phenotype.2-5 We
report here 2 siblings with transfusion-independent TI
who had immediate worsening of their clinical course and
became transfusion-dependent after splenectomy, and dis-
cuss how the absolute excess of α globin chains in these 2
patients may explain this development.
The father was diagnosed with TI at the age of 16 years
(baseline hemoglobin level 80-85 g/L) and the mother had
a normal hematologic profile. The 2 parents are not con-
sanguineous at least as far back as four generations,
although both are from a small village in the North East of
Italy. The 2 children were diagnosed with TI at the ages of
two and four years. The 2 children, who had never been
transfused before (baseline hemoglobin levels 75-80 g/L),
underwent splenectomy at the ages of ten and 12 years
because of splenomegaly and secondary anemia. Five
months following splenectomy, the clinical course of both
patients worsened and anemia (hemoglobin level <70 g/L)
necessitated initiating a transfusion regimen. Chelation
therapy was initiated at the ages of 14 and 19 years. The
younger child had thrombophlebitis at 17 years. The
father, now aged 51 years, shows a well tolerated chronic
hemolytic anemia without the need for transfusion (hemo-
globin level maintained at 80-85 g/L), mild jaundice,
splenomegaly and leg ulcers. The mother, still has a com-
pletely normal hematological profile and hemoglobin pat-
tern. 
The father and the 2 children were initially considered
to have unusual TI because at molecular analysis they
were carriers of a single b+ mutation (IVS1-110 G>A). After
the unusual clinical outcome following splenectomy, all
family members were referred to our center for molecular
reevaluation. As according to our center’s ethical commit-
tee guidelines, all family members signed written informed
consent to molecular studies for both diagnostic and
research purposes. DNA analysis of b and α globin genes
was performed. Mutation analysis of the b globin gene
was established by direct DNA sequencing on the ABI
Prism 310 genetic analyzer (PE Biosystems Foster City CA,
USA). The α globin gene cluster was analyzed by
Multiplex Ligation-dependent Probe Amplification
(MLPA) according to Harteveld et al.4,6 RNA analysis was
performed in triplicate on TaqMan 7500 (PE Biosystems
Foster City, CA, USA) after DNAse treatment using specif-
ic gene assay  (HBA1/2: Hs00361191_g1). The relative
quantification (RQ) of alpha genes expression was
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Figure 1. (A) Schematic representation of the 750 Kb region from the telomere of the short arm of chromosome 16 analyzed by
Multiplex Ligation-dependent Probe Amplification (MLPA). The position of the 35 MLPA-probe pairs along the region is indicated by green,
red and blue arrows, referring to HEX, ROX and FAM labeling, respectively. The duplicated region is indicated as arched red bars and
spans at least 175 Kb. (B) Real-time polymerase chain reaction experiments: the graphs show the mean and standard deviation of three
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achieved by normalization against two different house-
keeping genes Beta-actine (ACTB:Hs99999903_m) and b2
microglobuline (b2M:Hs00187842-m1) using the 2-ΔΔct for-
mula.
Molecular analysis confirmed that the father and the 2
children were heterozygotes for the b+ mutation IVSI-110
G>A. MLPA analysis disclosed a full duplication of the α
globin locus spanning at least 175 kb, from the telomere to
the 3’HVR downstream of the α globin gene, including the
upstream regulatory element HS-40 (Figure 1A).4 This
rearrangement increases the number of functional α globin
genes in cis from 2 to 4 and was found in heterozygosis in
both parents and in homozygosis in both children. The
overproduction of alpha chains was confirmed by Q-PCR
experiments with RQ increased in all members of the fam-
ily (Figure 1B). As expected, the parents showed RQ values
of about 1.5 while the children showed values of about 2.
Hematologic and molecular data of the family are summa-
rized in Table 1. 
In the father, coinheritance of a b globin mutation with
6 α globin genes led to a moderate-severe, well tolerated
TI phenotype. The 2 children had 8 functional α globin
genes (since the regulatory element HS-40 was also dupli-
cated) producing a large amount of α chains (twice than
normal) that, associated with reduced b chain production,
causes a severe α/b globin imbalance.
In transfusion-independent TI, erythropoietic stress,
ineffective erythropoiesis, and chronic intravascular
hemolysis are highly variable. An increased number of ery-
throblasts, reticulocytes, and damaged erythrocytes are
seen in the peripheral blood. The excess free α chains pre-
cipitate within the erythroid precursors, form hemi -
chromes, and alter the membrane cytoskeletal proteins by
clustering band 3 and enhancing deposition of opsonin
autologous immunogobulins and C3 fragments.7-8 About
80% of senescent or altered erythrocytes are removed
extravascularly by macrophages present mainly in the
spleen.7 Thus, removal of the spleen in patients with an
absolute excess of α chains, as in our patients, may lead to
more severe hemolysis and persistence of damaged ery-
throblasts and erythrocytes in the blood stream compared
to patients with defective b chain production and a relative
excess of α chains. These persistent abnormal erythroid
cells may justify the high rate of thromboembolism in
splenectomized TI patients,9-10 including the one reported
herein. They acquire procoagulant properties from
increased exposure of phosphatidylserine instead of phos-
phatidyletanolamine on their outer surface, by an altered
flip flop mechanism mediated by band 3 clusters.11 Thus,
in the 2 siblings, splenectomy was associated with an
increase in the number of nucleated red blood cells (as doc-
umented in the blood smear), increased peripheral hemol-
ysis (worsening anemia), and increased risk of thrombotic
events (in one of the children).
In the light of several reports linking splenectomy to
adverse long-term outcomes, it was recently recommend-
ed that the decision to perform a splenectomy in TI
patients should be taken with caution and the procedure
should be avoided or delayed unless absolutely necessary.1
Given our experience,we agree with this recommendation,
especially in TI patients characterized by a severe imbal-
ance between α/non-α globin chains due to an absolute
excess of α globin chains. We also recommend including α
globin gene testing in the molecular workup of patients
with TI where the b gene defect does not completely
explain the observed phenotype.
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Table 1. Hematologic and molecular data of the family at the time of study.
Age/ Hb RBC MCV MCH Hb Hb RBCn Spleen LDH Transf Chelation α genes b genes α/b genes
gender g/ L ¥1012/L fL pg A2 % F % % U/L
Mother 46/F 128 4.87 81.7 26.3 2.5 0.9 0 normal 245 no no αα,αα/αα bN/bN 1.5
Father 51/M 85a 4.47 64.0 19.0 5.0 3.7 13 20 cm 356 no no αα,αα/αα bT/bN 3
Child 1 19/M 60b 3.80 60.0 16.5 4.3c 7.5d 40e splenectomy 642 yes yes αα,αα/αα,αα bT/bN 4
Child 2 14/F 59b 3.69 59.9 16.0 4.0c 7.7d 45e splenectomy 689 yes yes αα,αα/αα,αα bT/bN 4
aBaseline 80-85 g/L; bBaseline 75-80 g/L; cBaseline 4%; dBaseline 6%; eBaseline <15%. F: female; M: male; Hb: hemoglobin; RBC: red blood cells; MCV: mean corpuscular volume; MCH:
mean corpuscular hemoglobin; RBCn: nucleated red blood cells (orthochromatic erythroblasts); LDH: lactate dehydrogenase; Transf: transfusion-dependence.
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Analysis of NOTCH1 mutations in monoclonal 
B-cell lymphocytosis
Monoclonal B-cell lymphocytosis (MBL) represents
asymptomatic monoclonal B-cell expansions characterized
by a chronic lymphocytic leukemia (CLL) phenotype, but
with less than 5.0¥109/L circulating cells.1-3 Clinical MBL
(cMBL) is recognized during the diagnostic workup of an
asymptomatic lymphocytosis.4-6 Although the molecular
pathogenesis of MBL is little known, the biological indo-
lence of this condition is documented by the rare occur-
rence of genetic lesions predicting poor prognosis in CLL,
such as TP53 and ATM disruption.4-6
Recently, two independent investigations of the CLL
coding genome have revealed that activating mutations of
the NOTCH1 proto-oncogene occur in approximately
10% CLL at diagnosis and their frequency increases in
advanced disease phases, exemplified by the case of
Richter syndrome.7,8 Initial evidence suggests that
NOTCH1 alterations might predict an unfavorable clinical
outcome in CLL. The prevalence of NOTCH1mutations in
MBL is currently unknown.7-11
Here we investigated the occurrence of NOTCH1muta-
tions in 63 consecutive cMBL presenting at our clinic for
the initial evaluation of an asymptomatic lymphocytosis.
The cMBL cohort was provided with prospectively collect-
ed peripheral blood mononuclear cell samples drawn at
presentation, and with a prospectively maintained clinical
database. All cMBL were analyzed for NOTCH1, TP53 and
IGHVmutations by DNA Sanger sequencing, and for FISH
karyotype using the LSI13 and LSID13S319, CEP12,
LSIp53 and LSIATM probes (Abbott, Rome, Italy).5,7 A
NOTCH1 mutation (c.7544_7545delCT) that is known to
be highly recurrent in CLL was also independently inves-
tigated by amplification refractory mutation system
(ARMS) PCR. Patients provided informed consent in accor-
dance with local IRB requirements and the Declaration of
Helsinki. The study was approved by the Ethical
Committee of the Ospedale Maggiore della Carità of
Novara, Northern Italy, associated with the Amedeo
Avogadro University of Eastern Piedmont (Protocol Code
59/CE; Study Number CE 8/11). 
The clinical profile of the cMBL cohort was representa-
tive of this condition. Median age was 68 years (range 40-
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Figure 1. NOTCH1 mutations
in clinical monoclonal B-cell
lymphocytosis. Sequencing
traces of the two clinical mon-
oclonal B-cell lymphocytosis
tumor samples (case 1 and
case 2) harboring the NOTCH1
c.7544_7545delCT mutation
(RefSeq NM_017617.2);
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